Gene therapy for a type of inherited vision loss
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
This study is working on a new gene therapy to help people with a specific type of vision loss called autosomal recessive retinitis pigmentosa, which is caused by changes in the CNGB1 gene, by using a special virus to deliver the correct gene to the eye and hopefully improve vision and protect the eye from further damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10368093 on NIH RePORTER |
What this research studies
This research focuses on developing a gene therapy approach for treating autosomal recessive retinitis pigmentosa (arRP) caused by mutations in the CNGB1 gene. The project aims to optimize a viral vector that can deliver the correct gene to the affected rod photoreceptors in the retina. By using animal models that mimic the human condition, the researchers will assess the effectiveness of this therapy in restoring vision and preventing further degeneration of retinal cells. The ultimate goal is to prepare for a clinical trial that could bring this innovative treatment to patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autosomal recessive retinitis pigmentosa linked to CNGB1 mutations.
Not a fit: Patients with other forms of retinitis pigmentosa or those without CNGB1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from a currently untreatable form of inherited vision loss.
How similar studies have performed: Previous research has shown promising results with gene therapy approaches in similar retinal conditions, indicating potential for success in this novel application.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Petersen-Jones, Simon — Michigan State University
- Study coordinator: Petersen-Jones, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.